


Our Expertise

Avance Biosciences, a licensed Guide-Seq service provider, boasts extensive experience in assisting leading gene and cell therapy clients with the comprehensive characterization of their CRISPR-edited in vivo and ex vivo therapeutics. Our successful collaborations with prominent pharmaceutical and biopharmaceutical companies have contributed to the study of on/off-target profiles for their respective gene and cell therapy INDs. Reach out to us today to explore our on/off-target gene editing services and leverage our expertise in navigating the dynamic CRISPR gene editing domain.

conditions, while also enabling the assessment of the safety of gene-editing-based therapeutics.

Workflow

The GUIDE-Seq workflow involves integrating a double-stranded oligodeoxynucleotide (dsODN) at double-stranded breaks, followed by targeted amplification and sequencing to precisely identify and map off-target cleavage sites in CRISPR-edited genomes.





Critical Success Factors

Indicator Cell Selection

The choice of an indicator cell type is critical in the design of an effective Guide-Seq/iGuide experiment. It is
crucial that the indicator cell line closely mirrors the anticipated gene editing product. Cell lines displaying a
strong DNA repair response, such as HEK293 and CD4 T-cells, are advisable for heightened sensitivity in
detecting off-target effects.

Control Design

To reduce sequencing background noise during the data analysis phase, it is crucial to incorporate suitable
positive and negative controls in GUIDE-seq or iGUIDE experiments. This commonly entails sequencing
gene-edited samples alongside both naïve cells and positive controls.